Medicis (MRX) Lower Following Cut Q4, FY11 Outlook
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Join SI Premium – FREE
Medicis (NYSE: MRX) is nearly 9 percent lower Tuesday, in after-hours trading.
Earlier, the Company reported progress in reducing managed care restrictions for SOLODYN (minocycline HCl, USP) Extended Release Tablets and the Company's other therapeutic products.
The company also lowered its expected fourth-quarter EPS from a range of 63 to 69 cents to a range of 51 to 57 cents, and revs from $187 to $200 million to $170 to $183 million. Medicis also issued a lowered fiscal 2011 outlook. For more color, click here.
Earlier, the Company reported progress in reducing managed care restrictions for SOLODYN (minocycline HCl, USP) Extended Release Tablets and the Company's other therapeutic products.
The company also lowered its expected fourth-quarter EPS from a range of 63 to 69 cents to a range of 51 to 57 cents, and revs from $187 to $200 million to $170 to $183 million. Medicis also issued a lowered fiscal 2011 outlook. For more color, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Why SpaceX’s launch economics could keep Starlink ahead of Amazon Leo 12
- Buy this Shariah-compliant financial stock: BofA
- Benchmark explains why you should own this semiconductor stock
Create E-mail Alert Related Categories
Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
